Mixed urinary incontinence. Mixed incontinence
Conditions
Interventions
Intervention 1: Intervention group: Group receiving mirabegron 50 mg orally daily for up to 12 weeks. Intervention 2: Intervention group: Group receiving solifenacin 5 mg orally daily for up to 12 wee
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Clinical diagnosis of mixed urinary incontinence No use of antimuscarinic or beta-3 agonist medications for at least the past 3 months Able to complete a quality of life questionnaire Women aged 40 to 70
Exclusion criteria
Exclusion criteria: Pregnancy, breastfeeding, or planning to become pregnant during the study Severe stress urinary incontinence or pure stress incontinence Active urinary tract infection Bladder stones Bladder outlet obstruction Severe kidney or liver disease Uncontrolled hypertension Angle-closure glaucoma History of hypersensitivity to mirabegron, solifenacin, or similar drugs Neurological disorders affecting the bladder such as MS or Parkinson's disease History of bladder, urethral, ??or endoscopic urological procedures within the past 6 months Active bladder cancer or other malignancies involving the urinary system Use of interfering drugs such as anticholinergics, diuretics, or drugs affecting the QT interval Unwillingness or inability to comply with the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| I-QOL questionnaire score. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: I-QOL questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of drug side effects. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Self-expression. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Ali Hojjati
Shahid Beheshti University of Medical Sciences
Outcome results
None listed